Morbid obesity and Type 2 Diabetes are both major public health problems. Obesity is an important risk factor for Type 2 Diabetes. 90% of Type 2 Diabetes patients all over the world are overweight. Insulin resistance is the main problem in the metabolic syndrome leading to Type 2 Diabetes. Decreased insulin sensitivity and impaired beta cell function are the cause of type 2 diabetes, and insulin resistance is the link between obesity and type 2 DM. The occurrence of type 2 diabetes with obesity is not only related to the degree of obesity, but also the distribution of fat accumulation plays an important role, because the increased amount of fat around the abdomen is closely related to Type 2 Diabetes and heart diseases. Bariatric surgery has been proven to be effective in the treatment of obesity and Type 2 diabetes. Bariatric surgery is highly effective in providing long-term treatment of Type 2 Diabetes and provides sustainable weight loss. The surgeries that correct Type 2 Diabetes are called Diabetes Surgery among the people.
Since 2001, mini-gastric bypass (i.e. an anastomotic gastric bypass has been described as an effective alternative to RYGB in the treatment of morbid obesity and Type 2 Diabetes. and it should be “reversible.” These two options are also available with Mini Gastric Bypass.
Although there is not much evidence in the literature at the moment, Mini Gastric Bypass seems to be a promising option for the treatment of type 2 diabetes in obese and non-obese patients. It is becoming a more popular metabolic surgery method every day due to the good weight loss seen after Mini Gastric Bypass and the rapid improvement in Type 2 Diabetes.
Mini Gastric Bypass is a diabetes surgery that has become popular today because it is a method that has low complication rates, is easy to apply, has very good long-term weight control, is better than sleeve gastrectomy and is equal to RNY Bypass. In long-term follow-ups, there is no need for external vitamin and protein support.
+90 532 466 67 67